Brokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) PT at $17.33

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) have been given an average recommendation of “Buy” by the six brokerages that are presently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $17.33.

A number of equities research analysts have weighed in on TNYA shares. Canaccord Genuity Group reissued a “buy” rating and set a $16.00 target price on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital restated a “buy” rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a research report on Wednesday, December 18th. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a research report on Tuesday. Piper Sandler restated an “overweight” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Finally, Leerink Partners restated an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Synovus Financial Corp acquired a new position in shares of Tenaya Therapeutics during the 3rd quarter valued at $28,000. Geode Capital Management LLC lifted its position in shares of Tenaya Therapeutics by 5.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,296,156 shares of the company’s stock valued at $2,502,000 after acquiring an additional 66,968 shares during the period. XTX Topco Ltd lifted its position in shares of Tenaya Therapeutics by 51.2% during the 3rd quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock valued at $95,000 after acquiring an additional 16,687 shares during the period. Wellington Management Group LLP lifted its position in shares of Tenaya Therapeutics by 35.6% during the 3rd quarter. Wellington Management Group LLP now owns 294,133 shares of the company’s stock valued at $568,000 after acquiring an additional 77,235 shares during the period. Finally, State Street Corp lifted its position in shares of Tenaya Therapeutics by 0.9% during the 3rd quarter. State Street Corp now owns 1,058,898 shares of the company’s stock valued at $2,044,000 after acquiring an additional 9,506 shares during the period. Institutional investors and hedge funds own 90.54% of the company’s stock.

Tenaya Therapeutics Price Performance

TNYA opened at $1.47 on Monday. Tenaya Therapeutics has a fifty-two week low of $0.99 and a fifty-two week high of $7.01. The firm has a market capitalization of $116.45 million, a price-to-earnings ratio of -1.02 and a beta of 2.89. The company’s 50 day moving average price is $2.28 and its two-hundred day moving average price is $2.46.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.07. As a group, equities research analysts predict that Tenaya Therapeutics will post -1.35 EPS for the current year.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.